Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Oct 6, 2026
Scienture Holdings, Inc. (SCNX)
A forensic read on Scienture Holdings, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-0.9
Distress distance
Watch
Earnings quality
6
Forensic signals
-59.2%
ROE
215.9%
Revenue growth
The financial-health reading above compares this company's equity at BOOK value, not at what the market currently pays for it — this free snapshot doesn't pull live market data. Treat it as a rough read, not the final word.
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Scienture Holdings, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads -0.9, placing it in the Distress zone (based on book value, not market value, since this free snapshot doesn't pull live market data — treat this zone as a rough read, not the final word). 6 forensic signals were flagged in its latest SEC filings, led by inventory days.
What the filings flag
778d
FY2023→FY2025
Inventory days.Days inventory outstanding moved from 0 to 778 FY2023→FY2025 (against cost of goods sold; inventory +21946% vs -92% in cost of sales). Inventory is outrunning what's being sold — a flag for softening demand or obsolescence risk ahead. FY2023 and FY2025 aren't consecutive filed years here, so FY2025's opening balance can't be taken from FY2023 — both figures are measured on period-end balances rather than the beginning-plus-ending average, which keeps the two endpoints comparable to each other.
+153.9%/yr
FY2023–FY2025
Share-count dilution.Diluted share count changed +544% over the last 2 years to FY2025 (+153.9%/yr). The count is growing — 2.4M shares in FY2023, 15.3M in FY2025: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~153.9% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~84%.
479% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 479% of revenue in FY2025 — about $0.13 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 153.9% a year across FY2023–FY2025 and that rate is not falling, so total profit has to grow by that much annually before any of it reaches a share. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.
FCF ($14M)
FY2024
Shareholder returns.Returned $15M to shareholders (buybacks + dividends) in FY2024, but free cash flow was ($14M) after capex — there was no free cash flow to fund the payout from at all, and operating cash flow itself was negative or zero that year too. The entire return is coming from debt or cash reserves, not cash the business itself generated — a harder case than returns merely running ahead of free cash flow, since here there was none to run ahead of.
Key fundamentals
Latest Revenue$431,609.00
Revenue Growth YoY+215.9%
Revenue CAGR (2yr)-43.7%
Net Margin-9618.0%
Return on Equity-59.2%
Debt / Equity0.04x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Scienture Holdings, Inc.'s actual 10-K/10-Q/8-K filings?
Data from SEC EDGAR public filings · metrics as of Oct 6, 2026. Forensic signals flag probability, not certainty.
Scienture Holdings, Inc. (SCNX) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
618d DSO
FY2024→FY2025
Receivables vs revenue.Days sales outstanding moved from 30 to 618 days FY2024→FY2025 (receivables +6485% vs revenue +216%). Receivables are creeping up relative to sales. Across FY2023–FY2025 the day count ran 220 → 30 → 618 days, so the latest reading sits on top of a record that was flat or falling before it — one year's move, not a direction the business has been travelling in. Both figures are measured on period-end balances rather than the beginning-plus-ending average, because averaging needs the balance a year before every reading — FY2024's opening balance is on file, but across the 3 fiscal years read here (FY2023–FY2025) the average yields only 2 day counts (1 step), too few to tell a climb from one year's move.
$31M
FY2023–FY2025
Goodwill impairments.Took $31M of goodwill writedowns across 2 years (FY2023 ($5M), FY2025 ($26M)). Writedowns mean past acquisitions underperformed what was paid for them.